City Therapeutics Inc., an early-stage developer of RNAi-based drugs, raised $200 million in a US initial public offering priced at the mid-point of its marketed range.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
City Therapeutics Raises $200 Million in Upsized US IPO
